{"disease":{"id":"recurrent-head-and-neck-cancer","name":"recurrent head and neck cancer"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT02358031","title":"A Study of Pembrolizumab (MK-3475) for First Line Treatment of Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck (MK-3475-048/KEYNOTE-048)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":882,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":true},{"nct_id":"NCT05063552","title":"Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers","phase":"PHASE2, PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":430,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT04673929","title":"Transoral Robotic Surgery for rECurrent Tumours of the Upper Aerodigestive Tract","phase":"","overall_status":"COMPLETED","enrollment_count":278,"lead_sponsor_name":"Royal Marsden NHS Foundation Trust","has_results":true},{"nct_id":"NCT07195734","title":"Testing the Addition of Chemotherapy or Chemo-Immunotherapy to the Usual Surgery for Advanced Head and Neck Cancer","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":180,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT06022029","title":"A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":168,"lead_sponsor_name":"OncoNano Medicine, Inc.","has_results":false},{"nct_id":"NCT07405086","title":"Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":160,"lead_sponsor_name":"OHSU Knight Cancer Institute","has_results":false},{"nct_id":"NCT06589804","title":"Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":158,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT05136196","title":"BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":150,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT06662058","title":"Remote Audiometry to Monitor for Treatment-Related Hearing Loss in Patients With H&N SCC Receiving Cisplatin and/or Radiation","phase":"NA","overall_status":"RECRUITING","enrollment_count":118,"lead_sponsor_name":"Emory University","has_results":false},{"nct_id":"NCT03238378","title":"Salvage Brachytherapy and Hyperthermia for Recurrent H&N-tumours","phase":"NA","overall_status":"RECRUITING","enrollment_count":96,"lead_sponsor_name":"University of Erlangen-Nürnberg Medical School","has_results":false},{"nct_id":"NCT04260126","title":"Study of PDS0101 and Pembrolizumab Combination I/O in Subjects With HPV16 + Recurrent and/or Metastatic HNSCC","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":95,"lead_sponsor_name":"PDS Biotechnology Corp.","has_results":false},{"nct_id":"NCT04545957","title":"Jump: MR Simulation For Radiation Therapy Master Protocol","phase":"NA","overall_status":"RECRUITING","enrollment_count":86,"lead_sponsor_name":"Brigham and Women's Hospital","has_results":false},{"nct_id":"NCT03422536","title":"Ficlatuzumab w/wo Cetuximab in Patients w/Cetuximab-Resistant, Recurrent or Metastatic Head/Neck Squamous Cell Carcinoma","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":78,"lead_sponsor_name":"University of Arizona","has_results":true},{"nct_id":"NCT06869473","title":"Cetuximab Plus Platinum and Taxane-based Chemotherapy, Followed by Avelumab and Cetuximab, as First-line Treatment for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) Patients With a PD-L1 Combined Positive Score (CPS)≥1≤19.","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":67,"lead_sponsor_name":"Gruppo Oncologico del Nord-Ovest","has_results":false},{"nct_id":"NCT05039801","title":"IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":54,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT05172258","title":"Testing the Addition of an Anti-cancer Drug, Ipatasertib, to the Usual Immunotherapy Treatment (Pembrolizumab) in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":52,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT04474470","title":"A Study to Evaluate NT219 Alone and in Combination with ERBITUX® (Cetuximab) in Adults with Advanced Solid Tumors and Head and Neck Cancer","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":52,"lead_sponsor_name":"TyrNovo Ltd.","has_results":false},{"nct_id":"NCT02955290","title":"CIMAvax Vaccine, Nivolumab, and Pembrolizumab in Treating Patients With Advanced Non-small Cell Lung Cancer or Squamous Head and Neck Cancer","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":51,"lead_sponsor_name":"Roswell Park Cancer Institute","has_results":false},{"nct_id":"NCT06265285","title":"Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":50,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT03602079","title":"Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":49,"lead_sponsor_name":"Klus Pharma Inc.","has_results":false},{"nct_id":"NCT02289209","title":"Reirradiation With Pembrolizumab in Locoregional Inoperable Recurrence or Second Primary Squamous Cell CA of the Head and Neck","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":48,"lead_sponsor_name":"Dan Zandberg","has_results":true},{"nct_id":"NCT04862650","title":"Cemiplimab, Low-Dose Paclitaxel and Carboplatin for the Treatment of Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":46,"lead_sponsor_name":"Marcelo Bonomi","has_results":false},{"nct_id":"NCT04902027","title":"A Study of Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Recurrent/Metastatic Head and Neck Cancers","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":45,"lead_sponsor_name":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","has_results":false},{"nct_id":"NCT06980038","title":"Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":44,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT03049618","title":"Recombinant EphB4-HSA Fusion Protein and Pembrolizumab, MK-3475","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":42,"lead_sponsor_name":"University of Southern California","has_results":true},{"nct_id":"NCT05271604","title":"A Phase 2 Open Label Study of BA3021 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":42,"lead_sponsor_name":"BioAtla, Inc.","has_results":false},{"nct_id":"NCT02318771","title":"Radiation Therapy and MK-3475 for Patients With Recurrent/Metastatic Head and Neck Cancer, Renal Cell Cancer, Melanoma, and Lung Cancer","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":41,"lead_sponsor_name":"Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University","has_results":false},{"nct_id":"NCT06868433","title":"TMV Vaccine Therapy Alone and With Pembrolizumab for the Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":40,"lead_sponsor_name":"Emory University","has_results":false},{"nct_id":"NCT07156227","title":"Testing the Addition of an Anti-Cancer Drug, Camonsertib, to Radiation Therapy for Recurrent Head and Neck Squamous Cell Carcinoma","phase":"PHASE1","overall_status":"NOT_YET_RECRUITING","enrollment_count":39,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT05980000","title":"Ramucirumab and Pembrolizumab vs Pembrolizumab Monotherapy in PD-L1 Positive Head and Neck Squamous-Cell Carcinoma","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":37,"lead_sponsor_name":"Washington University School of Medicine","has_results":false},{"nct_id":"NCT01638533","title":"Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":37,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT04007744","title":"Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid Tumors","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":36,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT06636734","title":"Lovastatin and Pembrolizumab for the Treatment of Patients With Recurrent or Metastatic Head and Neck Cancer, LAPP Trial","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":28,"lead_sponsor_name":"Emory University","has_results":false},{"nct_id":"NCT05057247","title":"Duvelisib Plus Docetaxel In Recurrent/Metastatic HNSCC","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":26,"lead_sponsor_name":"Glenn J. Hanna","has_results":true},{"nct_id":"NCT06239220","title":"PD-L1 t-haNK, NAI IL-15sa and Cetuximab for Recurrent, Metastatic HNSCC","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":25,"lead_sponsor_name":"Glenn J. Hanna","has_results":false},{"nct_id":"NCT01727076","title":"Recombinant Interleukin-15 in Treating Patients With Advanced Melanoma, Kidney Cancer, Non-small Cell Lung Cancer, or Squamous Cell Head and Neck Cancer","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":20,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT03667482","title":"Cabozantinib in Combination With Cetuximab in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Cancer","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":20,"lead_sponsor_name":"Memorial Sloan Kettering Cancer Center","has_results":false},{"nct_id":"NCT03937141","title":"Efficacy and Safety Trial of ADU-S100 and Pembrolizumab in Head and Neck Cancer","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":16,"lead_sponsor_name":"Chinook Therapeutics, Inc. (formerly Aduro)","has_results":true},{"nct_id":"NCT03229278","title":"Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":14,"lead_sponsor_name":"Rutgers, The State University of New Jersey","has_results":true},{"nct_id":"NCT01846091","title":"Viral Therapy In Treating Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Cancer or Metastatic Breast Cancer","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":12,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT03754933","title":"Safety and Efficacy of Repeat Administration of Ad/PNP and Fludarabine Phosphate in Patients With Local Head/Neck Cancer","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":10,"lead_sponsor_name":"GeoVax, Inc.","has_results":true},{"nct_id":"NCT04514484","title":"Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":8,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT04576091","title":"Testing the Addition of an Anti-cancer Drug, BAY 1895344, With Radiation Therapy to the Usual Pembrolizumab Treatment for Recurrent Head and Neck Cancer","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":7,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT03642990","title":"NR in Chemo-induced Peripheral Neuropathy","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":5,"lead_sponsor_name":"Donna Hammond, PhD","has_results":true},{"nct_id":"NCT02842125","title":"Safety and Efficacy of Intra-Arterial and Intra-Tumoral Ad-p53 With Capecitabine (Xeloda) or Anti-PD-1 in Liver Metastases of Solid Tumors and Recurrent Head and Neck Squamous Cell Cancer","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":4,"lead_sponsor_name":"MultiVir, Inc.","has_results":false},{"nct_id":"NCT03991741","title":"Adoptive Cell Transfer of Autologous Tumor Infiltrating Lymphocytes and High-Dose Interleukin 2 in Select Solid Tumors","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":3,"lead_sponsor_name":"Gregory Daniels","has_results":true},{"nct_id":"NCT04969861","title":"BEMPEG With Pembrolizumab vs Pembrolizumab Alone in Patients With Metastatic or Recurrent HNSCC (PROPEL-36)","phase":"PHASE2, PHASE3","overall_status":"TERMINATED","enrollment_count":1,"lead_sponsor_name":"Nektar Therapeutics","has_results":true},{"nct_id":"NCT06872489","title":"Expanded Access Protocol for the Use of SL-28 in the Treatment of Advanced Solid Tumors","phase":"","overall_status":"AVAILABLE","enrollment_count":null,"lead_sponsor_name":"Second Life Therapeutics","has_results":false}],"total":48},"guidelines":[],"source":"Drug Landscape verified database"}